Alzheimer's Disease

Alzheimer’s disease is the most common form of dementia.  Dementia is a serious loss of mental capacity that can result in confusion and permanent loss of memory.  It is the third largest cause of death in Australia*. Alzheimer's disease is not a normal part of ageing, but a degenerative illness that impairs mental functions affecting memory, personality and intellect.

There were 245,400 people with dementia in Australia in 2009.  Unless something changes, Access Economics predicts that this will rise to around 1.1 million people by 2050. Most of us know someone personally who has suffered from Alzheimer’s disease, but some famous people who have experienced it include Ronald Reagan, Iris Murdoch and Hazel Hawke.

Symptoms and Causes

People with Alzheimer's disease usually deteriorate gradually, and the symptoms expressed will differ from one person to another.


Early Symptoms include Late Symptoms include


Forgetting major events and/or names of loved ones

Unusual irritability

Inability to care for one's self or home


Inability to manage daily responsbilities

Impaired decision making

Personality changes, sometimes including aggression


Difficulties sleeping, using the toilet and eating


Alzheimer's disease occurs when a protein called amyloid accumulates in the brain.  Brain cells are damaged when this protein reacts with copper and iron, which are abundant in the brain, in a chemical reaction similar to rusting.  The affected brain cells no longer effectively transmit information. 

A4 Trial

The A4 study is investigating a new drug intervention that may reduce the impact of a protein known as "amyloid" or "beta amyloid" plaques in the brain. Scientists believe that accumulation of amyloid in the brain may play a key role in the eventual development of AD-related memory loss. 

The A4 anti-amyloid investigational drug targets amyloid build-up in the brain with the aim of slowing memory loss associated with the development of AD. Recruitment for A4 has now ended, please check back for trial results as they become available.

View labs and projects

EARLY trial

Are you age 60 to 85 years?

Are you worried about memory loss in the future?

Please consider taking part in the EARLY Trial.

Do you have a history of Alzheimer’s disease (AD) in your family or do you think you may develop memory problems in the future? We are currently looking for healthy volunteers to participate in the EARLY Trial. 

The EARLY Trial is a global clinical research trial looking at the safety and efficacy of an investigational medication.

To find out if you might be able to take part in the EARLY Trial, continue to this brief questionnaire or visit to find out more.


View labs and projects

Useful information

If you are seeking more information on living with Alzheimer's disease please follow the link below.

Alzheimer's Australia

View labs and projects

Autosomal Dominant Alzheimer’s Disease

Autosomal Dominant Alzheimer’s Disease (ADAD) is a rare form of Alzheimer’s that causes memory loss and dementia in people in their 30s to 50s.

The Dominantly Inherited Alzheimer Network Trials Unit (DIAN‐TU) has launched the first prevention trial for ADAD families. The DIAN‐TU trial focuses on drugs that could potentially change the course of the disease. The trial’s goal is to determine the safety, tolerability, and effectiveness of these drugs. The DIAN‐TU trial will determine if these medications can prevent, delay, or possibly even reverse Alzheimer’s disease changes in the brain. Although there are differences between ADAD and the more common age‐associated, sporadic Alzheimer’s disease, the results of this study will have implications for future studies and treatments in sporadic Alzheimer's disease.

How You Can Help

Are you or someone you know affected by ADAD? We are currently looking for participants that have a parent or sibling who has been affected by an ADAD mutation. Please download the brochure for more information or contact Lesley Vidaurre